Stephen J. Williams, Member of the Board, Chief Scientific Officer, Senior Editor, PhD Pharmacology, BSc Toxicology
STEPHEN J. WILLIAMS, Ph.D.
Tel: 215 487 0259 (h)
610 331 1016 (c)
Email: sjwilliamspa@comcast.net
UPDATED on 11/9/2020
- Co-Editor Series D, Volume 4:
Human Reproductive System, Genomic Endocrinology and Cancer Types
http://www.amazon.com/dp/B08VTFWVKM
Available on Amazon.com since 2/2/2021
- NLP with INTERNS – Proof of Concept – on–going
- WIKIPEDIA ENTRY for LPBI & Aviva – REFERENCE GENERATION by 3rd party
- AI in Genomics & Cancer – Development of the PORTAL
- Interface with Blockchain vendor and NLP two vendors
Personal Bio
Personal Statement: My scientific career has centered on understanding the mechanisms underlying initiation of cancer, as well as the pharmacologic and toxicologic basis of chemotherapy. My research has focused on modeling the etiology and metabolic alterations of human ovarian cancer and malignant mesothelioma, using cellular, molecular and in-vivo strategies. Current research focuses on growth factor cell signaling in mesothelioma. Altogether, my research goals have concentrated on the cellular stresses, and the resultant genetic and metabolic alterations which provide not only a fertile micro-environment for oncogenesis, tumor progression and disease etiology but also an opportunity for therapeutic development
Biography: For the onset of my scientific career I entered one of the first undergraduate toxicology programs in the country, at the Philadelphia College of Pharmacy & Science, and trained in various methodologies in toxicology and pharmacology, including research into effects of leukotrienes and leukotriene antagonists on gastrointestinal motility. I continued with my research training at the University of Pennsylvania Institute for Environmental Medicine, studying the effects of hyperbaric oxygen, and free radicals on lung function and the pathology of Sudden Infant Death Syndrome. I subsequently received my PhD in Pharmacology from Temple University, with my thesis, under Dr. Michael Sirover, involving the biochemical and pharmacologic effects on noncanonical protein functions in metabolism and DNA repair. Afterward, I continued with postdoctoral training in the Department of Pharmacology under an NCI-PRAT fellowship and in the Ovarian Cancer Program in the laboratory of Dr. Thomas Hamilton. My research involved determination of mechanisms of cisplatin resistance in ovarian cancer, discovering genes causal in early ovarian oncogenesis, and development of animal ovarian tumor models useful for determining ovarian cancer driver genes, determining chemotherapeutic efficacy, and development of imaging and surrogate tumor biomarker methods for detection of ovarian tumor burden in in-vivo ovarian cancer models. To this end, I developed one of the first, and patented, porcine ovarian tumor models, and with colleagues, additional models to measure intraperitoneal ovarian cancer using both surrogate tumor markers and MRI imaging methodology useful for chemotherapeutic evaluation.
As scientific research and information was entering a new explosive age of massive data, I decided to assist Dr. Aviva Lev Ari in her venture Leaders in Pharmaceutical Business Intelligence, in developing a methodology of scientific curation, in collaboration with Dr. Larry Bernstein and a worldwide network of expert scientists and clinicians. This effort culminated in the development of an influential web 2.0 platform for the curation, organization, and dissemination of scientific and biomedical findings in addition of the creation of 16 medical e-books on multiple topics. As such I became senior editor on two volumes, an e-book series on Cancer and a series on Genomics.
Concurrently I was designated an adjunct professor in Temple University College of Science & Technology, teaching a course on Cell Signaling and Cancer Biology, as well as an associate professor in the Sbarro Health Research Organization where I head the grants department including grants management and administration. Currently I also decided to continue my research efforts into understanding events causal in early oncogenesis and joined the research organization ISOPROG, where we have been researching autocrine growth factor loops involved in the malignant phenotype in mesothelioma and other cancer types.
As a result of the aforementioned endeavors, I have multiple peer-reviewed publications and book chapters as well as whole books in the fields of cancer, genomics, and personalized oncology. In addition, I am a frequent reviewer for such journals such as Cancer Research, Cancers, the Journal of Cellular Physiology, and others. I am a member of the AAAS, AACR, Mid Atlantic Pharmacology and Mid Atlantic Toxicology Society.
AREAS OF EXPERTISE
- Molecular Biology and Biochemistry: Transitional research, recombinant DNA technologies; RNA/DNA purification and analysis; real-time PCR and primer design; DNA methylation; Western analysis (quantative); ELISA; DNA repair assays; enzyme kinetics; analysis of cellular redox status; protein modification; enzyme and protein purification; column chromatography; HPLC; immunohistochemistry; reporter gene assays.
- Cellular: Primary cell culture and isolation; development and establishment of cell lines (primary and tumorigenic, stable lines generation); flow cytometry; Guava single cell analysis; soft agar colony assay; cell proliferation/toxicity assays; in-vitro transformation.
- In-Vivo: Small animal handling and colony maintenance; development of animal models of ovarian cancer; in-vivo preclinical drug evaluation; necropsy and gross pathology; small animal imaging.
Curriculum Vitae
SCIENCE Side Member
Responsibilities @LPBI:
(1) Curator initiated new content creation
(2) Updates to own published articles in the Journal
(3) Commissions by the Editor-in-Chief – One curation per WEEK
(4) Client facing engagement with External relations
(5) Advice for the Founder
Roles on 2.0 LPBI Group’s TNS #1,2,3,4,5,6 https://pharmaceuticalintelligence.com/vision/
(1) TNS #1: https://www.wolfram.com/featureset/machine-learning/
1.1 LPBI LEAD on Comparison of NLP results obtained for Microsoft AZURE and EXPERIMENT with Text Analysis The Wolfram Language
1.2 LPBI LEAD on Application on the ingress TEXT from: Cancer Volume 1 &2 and Genomics Volume 1&2
1.3 LPBI LEAD on Phase 3: Scaling up NLP, ML, AI to LPBI Group’s FOUR Corpuses Using LPBI’s Vendor of Choice:
- The Wolfram Solution for Biological Sciences
- The Wolfram Data Drop is an open service that makes it easy to accumulate data of any kind, from anywhere—setting it up for immediate computation, visualization, analysis, querying, or other operations
(2) TNS #2: Blockchain Transactions and broadcasting to communities in the Health Care Sector – THE ONLY WAY TO MONETIZE our content by narrow casting to Health Care Communities: BustIQ – lined them up and are willing to build the Front End
(3) Co-Editor LPBI Group’s BioMed Book #17 – COMPLETE Editorials by 12/10/2020
Publications with Leaders in Pharmaceutical Business Intelligence (LPBI) Group
Series A: e-Books on Cardiovascular Diseases
Volume One: Perspectives on Nitric Oxide
Sr. Editor: Larry Bernstein, MD, FCAP, Editor: Aviral Vatsa, PhD and Content Consultant: Stephen J Williams, PhD
http://www.amazon.com/dp/B00DINFFYC
Series C: e-Books on Cancer & Oncology
Volume 1:
Cancer Biology and Genomics for Disease Diagnosis
http://www.amazon.com/dp/B013RVYR2K
Volume 2:
Cancer Therapies: Metabolic, Genomics, Interventional, Immunotherapy and Nanotechnology in Therapy Delivery
http://www.amazon.com/dp/B071VQ6YYK
Series B: Frontiers in Genomics Research
Volume 1:
Genomics Orientations for Personalized Medicine
http://www.amazon.com/dp/B018DHBUO6
Volume 2:
Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS & BioInformatics, Simulations and the Genome Ontology
PUBLICATIONS in Open Access Online Scientific Journal
https://pharmaceuticalintelligence.com/
Cancer
Williams, S.J. July 1, 2014. Good and Bad News Reported for Ovarian Cancer Therapy
Williams, S.J. June 17, 2014. Can Mobile Health Apps Improve Oral-Chemotherapy Adherence? The Benefit of Gamification.
Williams, S.J. June 11, 2014. The SCID Pig II: Researchers Develop Another SCID Pig, And Another Great Model For Cancer Research
Williams, S.J. May 6, 2014. The Cancer Research Concentration @ Leaders in Pharmaceutical Business Intelligence
Williams, S.J. April 4, 2014. Heroes in Medical Research: Developing Models for Cancer Research
Williams, S.J. January 3, 2014. Loss of Gene Islands May Promote a Cancer Genome’s Evolution: A new Hypothesis on Oncogenesis
Williams, S.J. November 23, 2013. Liver Toxicity halts Clinical Trial of IAP Antagonist for Advanced Solid Tumors
Williams, S.J. October 11, 2014. The SCID Pig: How Pigs are becoming a Great Alternate Model for Cancer Research
Williams, S.J. September 4, 2013. Issues in Personalized Medicine: Discussions of Intratumor Heterogeneity from the Oncology Pharma forum on LinkedIn
Williams, S.J. August 7, 2013. Nitric Oxide Mitigates Sensitivity of Melanoma Cells to Cisplatin
Williams, S.J. June 13, 2013. Combining Nanotube Technology and Genetically Engineered Antibodies to Detect Prostate Cancer Biomarkers
Williams, S.J. May 30, 2013. New scheme to routinely test patients for inherited cancer genes
Williams, S.J. April 17,2013. Heroes in Medical Research: Dr. Robert Ting, Ph.D. and Retrovirus in AIDS and Cancer
Williams, S.J. April 10, 2013. Issues in Personalized Medicine in Cancer: Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Williams, S.J. March 13, 2013. Personalized Medicine: Clinical Aspiration of Microarrays
Williams, S.J. March 12, 2013. AMPK Is a Negative Regulator of the Warburg Effect and Suppresses Tumor Growth In Vivo
Williams, S.J. February 10, 2014. Rewriting the Mathematics of Tumor Growth; Teams Use Math Models to Sort Drivers from Passengers
Williams, S.J. February 3, 2013. Genome-Wide Detection of Single-Nucleotide and Copy-Number Variation of a Single Human Cell
Williams, S.J. January 12, 2013. Heroes in Medical Research: Barnett Rosenberg and the Discovery of Cisplatin
Williams, S.J. January 3, 2013. Differentiation Therapy – Epigenetics Tackles Solid Tumors
Williams, S.J. November 30, 2012. Prostate Cancer Cells: Histone Deacetylase Inhibitors Induce Epithelial-to-Mesenchymal Transition
Williams, S.J. October 31, 2012. How Mobile Elements in “Junk” DNA Promote Cancer – Part 1: Transposon-mediated Tumorigenesis
Williams, S.J., reporter, June 19, 2014. Second Annual Single-Cell Sequencing of Cancer Rountable August 20,21, 2014 Washington DC
Williams, S.J. March 27, 2013. Ethical Concerns in Personalized Medicine: BRCA1/2 Testing in Minors and Communication of Breast Cancer Risk
Toxicology
Williams, S.J. November 20, 2012. FDA Guidelines For Developmental and Reproductive Toxicology (DART) Studies for Small Molecules
Williams, S.J. November 7, 2012. Report on the Fall Mid-Atlantic Society of Toxicology Meeting “Reproductive Toxicology of Biologics: Challenges and Considerations:
Williams, S.J. October 29, 2013. Heroes in Medical Research: Dr. Carmine Paul Bianchi Pharmacologist, Leader, and Mentor
Williams, S.J. February 24, 2013. Mobilizing Scientific Societies: Editorial by Science Editor-in-Chief Dr. Bruce Alberts
Williams, S.J. September 24, 2012. Nitric Oxide Covalent Modifications: A Putative Therapeutic Target?
https://pharmaceuticalintelligence.com/2012/09/24/nitric-oxide-covalent-modifications-a-putative-therapeutic-target/
Williams, S.J. May 14, 2014. The Bioscience Crowdfunding Environment: The Bigger Better VC?
https://pharmaceuticalintelligence.com/2014/05/14/the-bioscience-crowdfunding-environment-the-bigger-better-vc/
Williams, S.J. February 24, 2014. Tycho Brahe, where art thou? Today’s Renaissance of the Self-Funded Scientist!
Williams, S.J. May 15, 2013. Finding the Genetic Links in Common Disease: Caveats of Whole Genome Sequencing Studies